Search results
Moderna Shares Jump After Better-Than-Expected Sales
The Wall Street Journal· 3 days agoModerna shares shot up about 7% Thursday after reporting better-than-expected quarterly sales and signaling confidence in a sales pickup later this year....
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga· 3 days agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 3 days agoAnd help us understand, as you've communicated with large retail pharmacy, how significant the PFS formulation is to them? A: (Stephane Bancel - CEO & Director ...
Biotech’s bind over China bill
Politico· 2 days agoCEO Stéphane Bancel touted the vaccine candidate’s safety and efficacy data as “stronger” than competitors’ though another company official noted Moderna ...
Moderna Stock Takes Minimal Hit After New COVID Vaccine Topped Projected Estimates
Black Enterprise· 2 days agoModerna announced an increase in stock price after their COVID vaccine exceeded sales estimates for...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 3 days agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 3 days agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 3 days agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its COVID-19 vaccine.
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Digital Journal· 3 days agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 ...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 3 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter revenue is down ...